Trending Now
Aytu Bioscience Inc (NASDAQ:AYTU) Reports An Impressive Fiscal Q4 2020 Performance
Aytu Bioscience Inc (NASDAQ:AYTU) recently released its financial report for its fiscal Q4 2020 ended June 30, 2020, revealing impressive financial highlights.
The company’s net...
DIH Holding US, Inc. (DHAI): Pioneering Rehabilitation with Cutting-Edge Technology
Let’s talk about something truly inspiring: the future of rehabilitation. On December 23, 2024, DIH Holding US, Inc. (NASDAQ: DHAI) announced...
Predictive Oncology Inc. (Nasdaq: POAI): A Transformative Acquisition by Renovaro Inc.
The biotechnological domain is currently abuzz with developments surrounding the acquisition of Predictive Oncology Inc. (Nasdaq: POAI) by Renovaro Inc. (Nasdaq: RENB)....
Popular News
Compugen Ltd. (NASDAQ: CGEN) Announces New USPTO Covering Method Of Use...
Compugen Ltd. (NASDAQ: CGEN) has announced that the USPTO has granted it a new patent covering a method of use for COM701. COM701 is...
MAKE IT MODERN
LATEST REVIEWS
Tonix Pharmaceuticals Holding Corp (NASDAQ: TNXP) To Commence Construction of New...
Tonix Pharmaceuticals Holding Corp (NASDAQ: TNXP) plans to hold a groundbreaking ceremony at its planned 45,000 sq. ft. clinical scale manufacturing plant in the...
MAKE IT MODERN
PERFORMANCE TRAINING
Mesoblast’s (NASDAQ: MESO) Breakthrough: A New Horizon in Pediatric Treatment Sparks Investor Excitement”
Exciting times are on the horizon for investors and traders closely following Mesoblast Limited (NASDAQ:MESO), as recent communications with the FDA suggest...
Is today’s surge in Dermata Therapeutics (DRMA) justified ?
Dermata Therapeutics, Inc. (Nasdaq:DRMA) is making significant strides with its focus on medical and aesthetic skin conditions. Recently, Dermata announced the successful...
Kadmon Holding Inc. (NASDAQ:KDMN) Announce Q3 2020 Results Ahead Of Commercial Launch Of Belumosudil...
Kadmon Holding Inc. (NASDAQ:KDMN) has announced its Q3 financial and operational results and also offered a business update.
Kadmon submits New Drug Application for belumosudil
Harlan...
I-Mab (NASDAQ: IMAB) Receives Approval in China for Second Phase Study Of Enoblituzumab Combination...
I-Mab (NASDAQ: IMAB) has announced that China’s National Medical Products Administration’s Centre for Drug Evaluation has approved its IND application to start the second...
Penny Stocks In Focus (TRKA, BTBT, IBRX)
Despite facing a challenging retail sales report and an unexpected decline in consumer spending for the month of March, the Dow Jones...




















































